Table 1.
Baseline participant characteristics and cross-sectional correlates of alkaline phosphatase.
Fig 1.
Hazard ratios for incident cardiovascular disease by baseline values of loge alkaline phosphatase using floating absolute risks.
A, adjusted for age and sex; B, adjustment as in A plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol; C, adjustment as in B plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge urine albumin excretion; D, adjustment as in C plus loge C-reactive protein; the size of the box is proportional to the inverse of the variance of hazard ratio.
Fig 2.
Hazard ratios for cardiovascular disease comparing top quintile versus bottom quintiles 1–4 of baseline ALP values, by several participant level characteristics.
Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol (HDL-C); CI, confidence interval (bars); CRP, C-reactive protein; CVD, cardiovascular disease; Estimated GFR, glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HR, hazard ratio; UAE, urinary albumin excretion; *, P-value for interaction; Cut-offs used for body mass index, total cholesterol, HDL-C, triglycerides, estimated GFR, and high sensitivity CRP are median values.
Table 2.
Association of alkaline phosphatase with incident cardiovascular disease, coronary heart disease, and stroke.
Table 3.
Associations of hsCRP with incident CVD, CHD and Stroke.
Table 4.
Risk discrimination and reclassification upon addition of ALP to the Framingham CVD risk prediction model containing conventional risk factors.